Sangamo BioSciences, Inc. (NASDAQ:SGMO) – Equities researchers at Jefferies Group raised their Q2 2017 earnings per share estimates for Sangamo BioSciences in a note issued to investors on Thursday. Jefferies Group analyst M. Raycroft now anticipates that the biopharmaceutical company will earn ($0.12) per share for the quarter, up from their previous forecast of ($0.29). Jefferies Group currently has a “Buy” rating and a $17.00 target price on the stock. Jefferies Group also issued estimates for Sangamo BioSciences’ Q3 2017 earnings at ($0.22) EPS, Q4 2017 earnings at ($0.23) EPS, FY2017 earnings at ($0.80) EPS, FY2018 earnings at ($0.17) EPS, FY2019 earnings at ($0.06) EPS, FY2020 earnings at $0.39 EPS and FY2021 earnings at $0.38 EPS.

Other research analysts also recently issued research reports about the company. Wedbush reiterated a “neutral” rating and set a $4.00 price target (down previously from $6.00) on shares of Sangamo BioSciences in a report on Tuesday, May 16th. ValuEngine upgraded Sangamo BioSciences from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Zacks Investment Research upgraded Sangamo BioSciences from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. Cowen and Company reiterated a “buy” rating on shares of Sangamo BioSciences in a report on Tuesday, February 28th. Finally, Piper Jaffray Companies reiterated a “neutral” rating and set a $5.00 price target on shares of Sangamo BioSciences in a report on Tuesday, February 28th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $8.50.

Earnings History and Estimates for Sangamo BioSciences (NASDAQ:SGMO)

ILLEGAL ACTIVITY NOTICE: “Research Analysts Issue Forecasts for Sangamo BioSciences, Inc.’s Q2 2017 Earnings (SGMO)” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/06/26/research-analysts-issue-forecasts-for-sangamo-biosciences-inc-s-q2-2017-earnings-sgmo.html.

Sangamo BioSciences (NASDAQ SGMO) opened at 9.30 on Monday. Sangamo BioSciences has a 52-week low of $2.65 and a 52-week high of $9.45. The stock’s market capitalization is $669.03 million. The company’s 50-day moving average price is $6.93 and its 200 day moving average price is $4.71.

Sangamo BioSciences (NASDAQ:SGMO) last released its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.03. Sangamo BioSciences had a negative return on equity of 50.76% and a negative net margin of 380.44%. The firm had revenue of $3.40 million for the quarter, compared to the consensus estimate of $4.14 million. During the same period in the prior year, the business posted ($0.23) earnings per share. The firm’s revenue for the quarter was down 12.8% compared to the same quarter last year.

A number of hedge funds have recently added to or reduced their stakes in SGMO. HighTower Advisors LLC boosted its stake in Sangamo BioSciences by 0.3% in the first quarter. HighTower Advisors LLC now owns 39,405 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 100 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Sangamo BioSciences by 0.4% in the first quarter. Dimensional Fund Advisors LP now owns 128,764 shares of the biopharmaceutical company’s stock worth $670,000 after buying an additional 513 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in Sangamo BioSciences by 1.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 49,713 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 780 shares during the last quarter. American International Group Inc. boosted its stake in Sangamo BioSciences by 7.1% in the first quarter. American International Group Inc. now owns 42,747 shares of the biopharmaceutical company’s stock worth $222,000 after buying an additional 2,818 shares during the last quarter. Finally, Teachers Advisors LLC boosted its stake in Sangamo BioSciences by 4.9% in the fourth quarter. Teachers Advisors LLC now owns 164,728 shares of the biopharmaceutical company’s stock worth $502,000 after buying an additional 7,693 shares during the last quarter. 59.23% of the stock is owned by hedge funds and other institutional investors.

Sangamo BioSciences Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Ratings for Sangamo BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.